Summary & Overview
HCPCS C9033: Fosnetupitant 235 mg and Palonosetron 0.25 mg Injection
HCPCS Level II code C9033 designates the injectable combination of fosnetupitant 235 mg and palonosetron 0.25 mg, a single-dose antiemetic used in chemotherapy supportive care. Nationally, this code matters because combination antiemetic products simplify administration, may influence site-of-care decisions, and affect hospital and clinic billing practices for chemotherapy prophylaxis.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of coverage considerations, typical places of service where C9033 is administered, and the clinical context for use in preventing chemotherapy-induced nausea and vomiting. The publication summarizes available benchmarks and payment context where available and highlights recent policy themes relevant to combination injectable antiemetics.
This analysis provides clinicians, billing professionals, and policy stakeholders with concise information on what C9033 represents, how it is typically used in outpatient infusion settings, and the payer landscape influencing access and billing workflows. Data not available in the input will be noted where applicable.
Billing Code Overview
HCPCS Level II code C9033 describes the injection formulation combining fosnetupitant 235 mg and palonosetron 0.25 mg. This code represents a single-dose, injectable antiemetic product combining a neurokinin-1 (NK1) receptor antagonist prodrug (fosnetupitant) and a 5-HT3 receptor antagonist (palonosetron) intended to prevent chemotherapy-induced nausea and vomiting.
Service Type: Intravenous injectable antiemetic administration
Typical Site of Service: Hospital outpatient infusion centers, oncology clinics, and other outpatient infusion settings where chemotherapy supportive care is administered.
Clinical & Coding Specifications
Clinical Context
A typical patient receiving C9033 is an adult oncology patient scheduled for moderately to highly emetogenic chemotherapy who requires a single intravenous fixed-dose combination antiemetic of fosnetupitant 235 mg and palonosetron 0.25 mg given prior to chemotherapy to prevent acute and delayed chemotherapy-induced nausea and vomiting. The clinical workflow begins with the oncology provider or infusion nurse reviewing the patient’s chemotherapy regimen and prior antiemetic response, confirming the indication and absence of allergies, obtaining verbal consent, and documenting baseline vital signs. The medication is prepared in the outpatient infusion center pharmacy under sterile conditions, delivered to the infusion chair, and administered as a single IV push or short infusion per product labeling immediately before chemotherapy. After administration, the patient is monitored for infusion reactions, vital sign stability, and common adverse effects (e.g., headache, constipation, dizziness). The infusion encounter is documented in the electronic medical record with the administered C9033 code, lot number, dosage, route, time of administration, and supervising clinician. Typical sites of service are outpatient oncology infusion centers, hospital outpatient departments, and ambulatory infusion suites. Common patient scenarios include: a patient receiving a highly emetogenic platinum- or anthracycline-based regimen, a patient with prior inadequate control of nausea/vomiting on other regimens, or a patient for whom oral antiemetics are contraindicated or impractical.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|